Cuevas, Mandy
Polk, Marie-Luise
Becker, Sven
Huppertz, Tilman
Hagemann, Jan
Bergmann, Christoph
Wrede, Holger
Schlenter, Wolfgang
Haxel, Boris
Bergmann, Karl-Christian
Klimek, Ludger
Funding for this research was provided by:
Technische Universität Dresden
Article History
Received: 26 October 2021
Accepted: 3 February 2022
First Online: 28 March 2022
Conflict of interest
: M. Cuevas reports personal fees from Novartis and Sanovi-Aventis, Allergopharma, HAL Allergie, Leti Pharma, and personal fees and nonfinancial support from AstraZeneca, GalaxoSmithKline, ALK, Bencard Allergie, Stallergenes, Roxall, as well as conducting studies for Lofarma, outside of the submitted work; and membership in the following organizations: AeDA, DGHNO. H. Wrede reports grants and/or honoraria from Allergopharma, MEDA/Mylan, Allergy Therapeutics/Bencard, HAL Allergy, LETI Pharma, Novartis, Stallergenes, Lofarma, GSK, Sanofi outside the submitted work; and membership in the following organizations: AeDA. L. Klimek reports grants and/or honoraria from Allergopharma, MEDA/Mylan, Allergy Therapeutics/Bencard, AstraZeneca, ASIT Biotech, HAL Allergie, ALK Abelló, LETI Pharma, Novartis, Stallergenes, Quintiles, Lofarma, GSK, Inmunotek, Sanofi, Thermofisher, outside the submitted work; and membership in the following organizations: AeDA, DGHNO, German Academy of Allergology and Clinical Immunology, GPA, EAACI. L. Klimek is the editor in chief of the Allergo Journal and Allergo Journal International in which this manuscript will be published. M.-L. Polk, S. Becker, T. Huppertz, J. Hagemann, C. Bergmann, W. Schlenter, B. Haxel and K.-C. Bergmann declare that they have no competing interests.